News
-
Quotient And Pulmatrix Announce Completion Of Innovative COPD Proof-Of-Concept Clinical Program
9/4/2012
Quotient Clinical, a leading provider of specialist early stage drug development services, and Pulmatrix, a clinical stage biotechnology company creating novel inhaled therapeutics, recently announced the completion of an early clinical program to achieve proof-of-concept data in COPD patients for PUR118, Pulmatrix’s lead iCALM (inhaled dry powder cationic airway lining modulator) therapeutic.
-
Novartis QVA149 Phase III Study Meets Primary Endpoint In Reducing Exacerbations In COPD Patients, Filing In EU And Japan By End Of Year
8/30/2012
Novartis announced recently that the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) Phase III study, SPARK, met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide (Seebri Breezhaler).
-
Pluristem Files For Orphan Drug Status With U.S. FDA For Use Of PLX Cells In Treatment Of Aplastic Anemia
8/30/2012
The filing marks Pluristem’s second orphan drug application to the U.S. FDA. The company applied once before, and successfully received in August of 2011, orphan drug status from the FDA for its PLX cell therapy in the treatment of Buerger’s disease.
-
ERT Introduces An Enhanced Platform To Streamline Data Collection, Analysis And Processing In Clinical Trials
8/28/2012
ERT, a global technology-driven provider of health outcomes services to biopharmaceutical organizations, medical device companies and contract research organizations (CROs), recently announced the launch of an enhanced clinical research workflow technology designed to streamline data collection, analysis and processing in clinical trials.
-
Teva To Initiate Third Phase III Trial Of Oral Laquinimod For The Treatment Of Relapsing Remitting Multiple Sclerosis
8/8/2012
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).
-
Pluristem’s PLX Cells Show Efficacy In Treating Lung Disease
7/31/2012
Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR), a leading developer of placenta-based cell therapies, recently announced the results of new preclinical tests that show its PLacental eXpanded (PLX) cells may be effective in reducing pulmonary fibrosis and improving lung function in a group of diseases collectively called interstitial lung disease (ILD). ILD includes the pulmonary insults occurring in the lung following its exposure to drugs, radiation or toxic chemicals and the pulmonary complications of systemic autoimmune diseases.
-
Synteract To Host Joint Statistical Meeting Roundtable In San Diego
7/24/2012
Synteract, Inc., a full-service contract research organization (CRO), will host the roundtable, “Beyond number-crunching and data-monitoring: challenging roles for CRO statisticians,” at the Joint Statistical Meetings (JSM), on August 1, 2012 at 12:30 p.m., PDT. The roundtable will be moderated by Jia Hu, biostatistician II, from Synteract. JSM is the largest gathering of statisticians held in North America, attended by more than 6,000 people.
-
Abbott Announces Initiation Of Phase 3 Study Of Elagolix In Patients With Endometriosis
6/5/2012
Abbott (NYSE: ABT), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist.
-
Halo Therapeutics Raises $1.1M To Expedite Phase 2 Study Of HT-100
5/22/2012
Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that it has received financial support totaling $1.1 million from 12 not-for-profit foundations serving the muscular dystrophy patient community.
-
Cerecor Announces Initiation Of CLIN01-002-A
5/21/2012
Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced that it has begun dosing of FP01 lozenges in CLIN01-002-A, an exploratory Phase II acute cough study in healthy subjects with upper respiratory tract infections (URTI).